The gene therapy regimen seems to be working wonders, including restoring nearly all hearing to a seven-year-old patient ...

In a new experimental study, scientists from Juntendo University in collaboration with researchers from the University of Tokyo have developed an adeno-associated virus (AAV) vector-mediated ...

Adeno-Associated Virus Vector in Gene Therapy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, and Companies by DelveInsight ...

The Global Adeno Associated Virus Vector Manufacturing Market was valued USD 759 Million in 2023 and projected to reach USD 3,700.6 Million by 2030, growing at a CAGR of 21.9% during the forecast ...

Adeno Associated Virus Vector Manufacturing Market Report Highlights By the scale of operations, the commercial segment dominated the industry in 2022.

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Adeno-associated virus is an attractive vector for gene therapy as it is non-pathogenic and integrates into a specific site in the human genome. In the December 11 Early Edition of the Proceedings of ...

Bioluminescent imaging is helping researchers better understand the effectiveness of tissue regeneration enhancers delivered to injured heart tissue by different adeno-associated virus vectors.

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The Adeno Associated Virus Vector Manufacturing market is characterized by a fragmented structure, with many competitors holding a significant share of the market.